Published in Oncoimmunology on December 18, 2015
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | NCT01740297
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | NCT02243371
Gemcitabine and CT-011 for Resected Pancreatic Cancer | NCT01313416
A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | NCT02349724
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | NCT02465983
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer | NCT01303172
Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol (2016) 0.79
Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatment. Oncotarget (2016) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Pancreatic cancer. N Engl J Med (2010) 13.88
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg (1999) 5.58
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 3.79
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol (2015) 3.57
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res (2006) 3.38
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol (2014) 3.15
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol (2015) 2.98
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg (1974) 2.14
European cancer mortality predictions for the year 2014. Ann Oncol (2014) 2.11
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res (1994) 1.90
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol (2014) 1.86
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res (2013) 1.60
Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res (2001) 1.55
Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett (2008) 1.53
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47
Abscopal effect in a patient with melanoma. N Engl J Med (2012) 1.39
Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev (2012) 1.38
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res (1988) 1.32
Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol (1991) 1.31
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 1.17
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res (2014) 1.17
How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis (1999) 1.14
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol (2012) 1.12
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs (2010) 1.09
The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res (1946) 1.09
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res (2006) 1.09
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res (2009) 1.08
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer (2011) 1.07
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res (2015) 1.05
Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res (2008) 1.04
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 1.01
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci (2004) 1.01
Immune reconstitution with donor-derived memory/effector T cells after orthotopic liver transplantation. Exp Hematol (1997) 0.98
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem (2010) 0.95
The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology (2014) 0.94
MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology (2005) 0.89
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep (2008) 0.89
Differential effects of Paclitaxel on dendritic cell function. BMC Immunol (2010) 0.88
The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res (2008) 0.87
Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res (2014) 0.86
Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Vaccine (2010) 0.84
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs (2007) 0.84
Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J Natl Cancer Inst (1985) 0.83
Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res (2010) 0.83
New insights into the mechanism of action of immune checkpoint antibodies. Oncoimmunology (2014) 0.82
RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol Immunother (2008) 0.81
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract. Surg Gynecol Obstet (1976) 0.81
Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81
Radiotherapy and toll-like receptor agonists. Semin Radiat Oncol (2015) 0.78
The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int (2014) 0.77
[Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors]. Arch Otorhinolaryngol (1982) 0.76
II. Hawkins on Tubercular Peritonitis. Ann Surg (1893) 0.76